These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 24333315)

  • 1. The evolution of the regulatory framework for the plasma and plasma-derived medicinal products system in Italy.
    Calizzani G; Vaglio S; Candura F; Profili S; Lanzoni M; Cristiano K; Tamburrini MR; Grazzini G; Oleari F
    Blood Transfus; 2013 Sep; 11 Suppl 4(Suppl 4):s6-12. PubMed ID: 24333315
    [No Abstract]   [Full Text] [Related]  

  • 2. Plasma-derived medicinal products in Italy: information sources and flows.
    Lanzoni M; Biffoli C; Candura F; Calizzani G; Vaglio S; Grazzini G
    Blood Transfus; 2013 Sep; 11 Suppl 4(Suppl 4):s13-7. PubMed ID: 24333305
    [No Abstract]   [Full Text] [Related]  

  • 3. [Guidelines on the use of medicinal plants].
    Battaglino G; Quercia V
    Boll Chim Farm; 1978 May; 117(5):251-7. PubMed ID: 743374
    [No Abstract]   [Full Text] [Related]  

  • 4. [The new norms decreed by the legislative dirrective 91-93 CCE].
    Neri M; Palazzo S
    Boll Chim Farm; 1998 Feb; 137(2):31-4. PubMed ID: 9595832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The problem of pesticide and heavy metal residues in plant-derived drugs used in the pharmaceutical industry].
    Lorusso S; Camoni I; Chiacchierini E
    Nuovi Ann Ig Microbiol; 1985; 36(3):169-80. PubMed ID: 3842759
    [No Abstract]   [Full Text] [Related]  

  • 6. Plasma-derived medicinal products self-sufficiency from national plasma: to what extent?
    De Angelis V; Breda A
    Blood Transfus; 2013 Sep; 11 Suppl 4(Suppl 4):s132-7. PubMed ID: 24333306
    [No Abstract]   [Full Text] [Related]  

  • 7. Regulatory status of medicinal products for human beings in the European Union. The role of generic products.
    Minghetti P
    Pharmacol Res; 1996; 34(1-2):3-7. PubMed ID: 8981548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The regulatory framework for complementary and alternative medicines in Europe].
    Knöss W; Stolte F; Reh K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):771-8. PubMed ID: 18584103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmaceutical specialities: definitions and rules for manufacturing and marketing in Italy].
    Germani C; Montanari L; Petraroja A
    Boll Chim Farm; 1979 Mar; 118(3):135-43. PubMed ID: 475905
    [No Abstract]   [Full Text] [Related]  

  • 10. [New pharmaceutical legislation in Italy and Federal Republic of Germany in relation to European Economic Community directives].
    Cavatorta L
    Boll Chim Farm; 1979 Mar; 118(3):144-62. PubMed ID: 475906
    [No Abstract]   [Full Text] [Related]  

  • 11. Sustainability of a public system for plasma collection, contract fractionation and plasma-derived medicinal product manufacturing.
    Grazzini G; Ceccarelli A; Calteri D; Catalano L; Calizzani G; Cicchetti A
    Blood Transfus; 2013 Sep; 11 Suppl 4(Suppl 4):s138-47. PubMed ID: 24333307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Review of the development in European Legislation on the harmonisation of the laws for medicinal products].
    Lehmann B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):713-21. PubMed ID: 18584107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clean drugs for Italy?
    Nature; 1993 Aug; 364(6439):658. PubMed ID: 8355770
    [No Abstract]   [Full Text] [Related]  

  • 14. [Large scale "monitoring" for drug safety].
    Ghione M
    Boll Chim Farm; 1971 Oct; 110(10):573-8. PubMed ID: 5143355
    [No Abstract]   [Full Text] [Related]  

  • 15. The regulatory framework for similar biotherapeutic products in Cuba.
    Hechavarría Núñez Y; Pérez Massipe RO; Orta Hernández SD; Muñoz LM; Jacobo Casanueva OL; Pérez Rodríguez V; Domínguez Morales RB; Pérez Cristiá RB
    Biologicals; 2011 Sep; 39(5):317-20. PubMed ID: 21930393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developing a European framework for research on children's medicines: an examination of the proposed EU regulation on medicinal products for paediatric use.
    Seyberth HW; Demotes-Mainard J; Wrobel P
    Pediatr Nephrol; 2005 Nov; 20(11):1537-40. PubMed ID: 16167134
    [No Abstract]   [Full Text] [Related]  

  • 17. [Technical-administrative aspects of the registration of pharmaceutical specialities].
    Marconi M; Battaglino G
    Boll Chim Farm; 1979 Mar; 118(3):118-34. PubMed ID: 475904
    [No Abstract]   [Full Text] [Related]  

  • 18. Plasma and plasma-derived medicinal product self-sufficiency: the Italian case.
    Calizzani G; Profili S; Candura F; Lanzoni M; Vaglio S; Cannata L; Catalano L; Chianese R; Liumbruno GM; Grazzini G
    Blood Transfus; 2013 Sep; 11 Suppl 4(Suppl 4):s118-31. PubMed ID: 24333304
    [No Abstract]   [Full Text] [Related]  

  • 19. [Medicines: if their added value is not made explicit.].
    Formoso G; Font Pous M
    Recenti Prog Med; 2017 Feb; 108(2):75-76. PubMed ID: 28287200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Off-patent drugs in Italy. A short-sighted view?
    Garattini L; Ghislandi S
    Eur J Health Econ; 2006 Mar; 7(1):79-83. PubMed ID: 16425040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.